Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page # ]' E4 i1 }) ^5 L. ?/ e: ?
, h0 e3 H( ^2 o4 v" Z/ x8 J0 M# u- J. C5 x' E3 S( L- K
Sub-category:1 A+ }. w M- b. E
Molecular Targets
/ z0 q6 G0 o5 o& w$ J. _ g9 I4 [) C+ A6 ~ X
2 c4 k8 C a. t1 m) [8 W+ A3 ^; J, w. UCategory:
( N# f9 J) P* N! pTumor Biology
I! N( o7 _# e `$ C9 x/ z# D) f" H/ r1 U
9 S9 u$ M' n3 M+ N! PMeeting:, n0 S. g w6 z9 \# Y; ^
2011 ASCO Annual Meeting + _5 x. r# K! n
9 d9 ~; ^6 ?& a) C7 z9 x
1 _- I; r' d$ Z( OSession Type and Session Title:+ I3 C2 y4 m9 G
Poster Discussion Session, Tumor Biology
+ j' \; k/ v9 x7 c
. f5 Z) X* f5 [7 D4 \3 {. L; d+ @1 H% i8 B8 _& ~/ g
Abstract No:
2 E0 @, u& v) J: ?4 _10517
. O* m7 E0 C; Y' r- l5 U3 r; L% d7 Q' I' j
! n U6 r: f5 z: E4 B' oCitation:, r( _ W# e: j/ H. R( _ n" H
J Clin Oncol 29: 2011 (suppl; abstr 10517) * E7 ?, ?! i4 l; f$ c% J7 a
/ x8 ]* C/ B' o" ~
2 j; v/ H7 Y I6 \1 c
Author(s):/ a5 |! r7 E$ _1 A6 w+ ]7 [" j
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
: L q4 ?" w6 V! r. X( f' E, `7 c* Y& X$ P- d) P0 ^) H
& {! s+ Z; P) X* J# j* L
8 k( A2 A+ S H# \Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.4 w) f/ Q6 Z% t- E9 H
q' x) ]2 n! _& p# |
Abstract Disclosures& w9 ]% w" Y* E/ m# }
9 N1 R# Q0 ^0 {; K8 EAbstract:6 h ~9 p8 f6 u/ Z+ X
g3 B, H8 d& `9 @. b9 q- i0 k( {6 k& s8 D1 ?) d' h
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.6 r3 Z/ Z2 b1 ~/ w# w
Y& M, r: v9 ^6 V7 L 0 s6 g$ v$ _' V' k+ V
|
显身卡
